CoChat

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index; 30 of the 45 sources its claims cite were checked for support.

Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials

Open access

Abstract

Background In the STEP-HFpEF (NCT04788511) and STEP-HFpEF DM (NCT04916470) trials, the GLP-1 receptor agonist semaglutide improved symptoms, physical limitations, bodyweight, and exercise function in people with obesity-related heart failure with preserved ejection fraction. In this prespecified pooled analysis of the STEP-HFpEF and STEP-HFpEF DM trials, we aimed to provide a more definitive assessment of the effects of semaglutide across a range of outcomes and to test whether these effects were consistent across key patient subgroups. Methods We conducted a prespecified pooled analysis of individual patient data from STEP-HFpEF and STEP-HFpEF DM, randomised, double-blind, placebo-controlled trials at 129 clinical research sites in 18 countries. In both trials, eligible participants were aged 18 years or older, had heart failure with a left ventricular ejection fraction of at least 45%, a BMI of at least 30 kg/m 2, New York Heart Association class II-IV symptoms, and a Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS; a measure of heart failure-related symptoms and physical limitations) of less than 90 points. In STEP-HFpEF, people with diabetes or glycated haemoglobin A 1c concentrations of at least 6·5% were excluded, whereas for inclusion in STEP-HFpEF DM participants had to have been diagnosed with type 2 diabetes at least 90 days before screening and to have an HbA 1c of 10% or lower. In both trials, participants were randomly assigned to either 2·4 mg semaglutide once weekly or matched placebo for 52 weeks. The dual primary endpoints were change from baseline to week 52 in KCCQ-CSS and bodyweight in all randomly assigned participants. Confirmatory secondary endpoints included change from baseline to week 52 in 6-min walk distance, a hierarchical composite endpoint (all-cause death, heart failure events, and differences in changes in KCCQ-CSS and 6-min walk distance); and C-reactive protein (CRP) concentrations. Heterogeneity in treatment effects was assessed across subgroups of interest. We assessed safety in all participants who received at least one dose of study drug. Findings Between March 19, 2021 and March 9, 2022, 529 people were randomly assigned in STEP-HFpEF, and between June 27, 2021 and Sept 2, 2022, 616 were randomly assigned in STEP-HFpEF DM. Overall, 1145 were included in our pooled analysis, 573 in the semaglutide group and 572 in the placebo group. Improvements in KCCQ-CSS and reductions in bodyweight between baseline and week 52 were significantly greater in the semaglutide group than in the placebo group (mean between-group difference for the change from baseline to week 52 in KCCQ-CSS 7·5 points [95% CI 5·3 to 9·8]; p<0·0001; mean between-group difference in bodyweight at week 52 -8·4% [-9·2 to -7·5]; p<0·0001). For the confirmatory secondary endpoints, 6-min walk distance (mean between-group difference at week 52 17·1 metres [9·2 to 25·0]) and the hierarchical composite endpoint (win ratio 1·65 [1·42 to 1·91]) were significantly improved, and CRP concentrations (treatment ratio 0·64 [0·56 to 0·72]) were significantly reduced, in the semaglutide group compared with the placebo group (p<0·0001 for all comparisons). For the dual primary endpoints, the efficacy of semaglutide was largely consistent across multiple subgroups, including those defined by age, race, sex, BMI, systolic blood pressure, baseline CRP, and left ventricular ejection fraction. 161 serious adverse events were reported in the semaglutide group compared with 301 in the placebo group. Interpretation In this prespecified pooled analysis of the STEP-HFpEF and STEP-HFpEF DM trials, semaglutide was superior to placebo in improving heart failure-related symptoms and physical limitations, and reducing bodyweight in participants with obesity-related heart failure with preserved ejection fraction. These effects were largely consistent across patient demographic and clinical characteristics. Semaglutide was well tolerated. Funding Novo Nordisk.

Overview

CoChat Summary

## TL;DR

In this prespecified pooled analysis of 1,145 patients with obesity-related HFpEF from the STEP-HFpEF and STEP-HFpEF DM trials, semaglutide 2.4 mg improved symptoms, physical function, exercise capacity, weight, and several biomarkers versus placebo. It also reduced adjudicated heart failure events, with a favorable safety profile and benefits generally consistent across subgroups.

## Key findings

  • The pooled dual primary endpoints favored semaglutide over placebo: KCCQ-CSS improved by +7.5 points (95% CI +5.3 to +9.8) and body weight fell by -8.4% (95% CI -9.2% to -7.5%) at week 52; both p<0.0001.
  • Semaglutide improved exercise capacity by +17.1 metres in 6-minute walk distance (95% CI +9.2 to +25.0; p<0.0001) and produced a higher win ratio for the hierarchical composite endpoint of 1.65 (95% CI 1.42 to 1.91; p<0.0001).
  • Biomarkers improved with semaglutide: CRP ratio to baseline 0.64 (95% CI 0.56 to 0.72; p<0.0001) and NT-proBNP ratio to baseline 0.82 (95% CI 0.74 to 0.91; p=0.0002).
  • Fewer adjudicated HF events occurred with semaglutide: 8/573 (1.4%) vs 30/572 (5.2%) with placebo; HR 0.27 (95% CI 0.12 to 0.56).
  • Treatment effects on KCCQ-CSS were generally consistent across prespecified subgroups, with larger symptom gains in more severe HFpEF subgroups; for example, the paper reports significant interactions by NYHA class, NT-proBNP, loop diuretic use, and atrial fibrillation history.

## Methods

  • Prespecified pooled analysis of individual patient data from two randomized, double-blind, placebo-controlled trials: STEP-HFpEF and STEP-HFpEF DM, conducted at 129 sites in 18 countries.
  • Included 1,145 randomized participants (529 from STEP-HFpEF and 616 from STEP-HFpEF DM); median age 69 years, 50% female, 90% White, and 65% had BMI ≥35 kg/m².
  • Participants were randomized 1:1 to once-weekly semaglutide 2.4 mg or placebo for 52 weeks; primary analyses used ANCOVA and logistic/Cox models with imputation, and subgroup analyses were prespecified across 14 subgroups.

## Limitations

  • The paper states that the number of clinical events, though larger than in the individual trials, was “likely still not large enough” to allow definitive conclusions about semaglutide’s efficacy in reducing HF events.
  • The authors state that there were relatively few non-White patients and too few patients outside North America and Europe for detailed race/geographic analyses, limiting generalizability.
  • The authors note that subgroup analyses were not individually powered and should be interpreted in that context.
  • The paper states that baseline kidney function data were not collected in STEP-HFpEF, preventing pooled subgroup analysis by kidney function.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(24)00469-0

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

9 Valid · 2 Not valid · 7 Not checked · 109 Own results and interpretations

56 more claims

Create a free account to see all 127 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 23
  • It may state two separate claims as one. 48
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 50 references

Cited by

See all 386

Metadata

Authors
Butler, J., Shah, S. J., Petrie, M. C., Borlaug, B. A., Abildstrøm, S. Z., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Verma, S., Einfeldt, M. N., Lindegaard, M. L., Rasmussen, S., Abhayaratna, W., Ahmed, F. Z., Ben-Gal, T., Chopra, V., Ezekowitz, J. A., Fu, M., Ito, H., Lelonek, M., Melenovský, V., Merkely, B., Núñez, J., Perna, E., Schou, M., Senni, M., Sharma, K., van der Meer, P., Von Lewinski, D., Wolf, D., & Kosiborod, M. N.
Affiliations
  • University of Mississippi Medical Center (US)
  • Northwestern University (US)
  • University of Glasgow (GB)
  • Mayo Clinic (US)
  • University of Leicester (GB)
  • Novo Nordisk (Denmark) (DK)
  • Wake Forest University Health Sciences (US)
  • St. Michael's Hospital (CA)
  • Australian National University (AU)
  • University of Manchester (GB)
  • Max Super Speciality Hospital (IN)
  • University of Alberta (CA)
  • Sahlgrenska University Hospital (SE)
  • Kawasaki Medical School (JP)
  • Medical University of Lodz (PL)
  • Institute of Clinical and Experimental Medicine (CZ)
  • Universitat de València (ES)
  • University of Copenhagen (DK)
  • Ospedale Papa Giovanni XXIII (IT)
  • Johns Hopkins University (US)
  • University of Freiburg (DE)
  • Saint Luke's Health System (US)
Corresponding author
Kosiborod, Mikhail N
Venue
The Lancet
Publisher
Elsevier BV
Published
2024-04
Volume
403
Issue
10437
Pages
1635-1648
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4394061375
Cited by
386
References
50
Citations by year
2026: 126 · 2025: 179 · 2024: 81
FWCI
115.52
Type
journal article
Language
en
Open access
Locations
  • The Lancet (acceptedVersion)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (acceptedVersion)
  • Pure Amsterdam UMC (submittedVersion, cc-by)
  • BOA (University of Milano-Bicocca) (submittedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion, cc-by-sa)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
Funders
Novo Nordisk A/S
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
semaglutide, heart failure with preserved ejection fraction, obesity, GLP-1 receptor agonists, type 2 diabetes, weight loss, Kansas City Cardiomyopathy Questionnaire, 6-minute walk distance, all-cause mortality, heart failure hospitalization, C-reactive protein, subgroup heterogeneity, individual patient data meta-analysis
MeSH terms
Semaglutide, Aged, Double-Blind Method, Glucagon-Like Peptides, Female, Heart Failure, Humans, Male, Middle Aged, Obesity, Stroke Volume, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. https://app.cochat.ai/papers/10.1016/s0140-6736(24)00469-0
The paper
Butler, J., Shah, S. J., Petrie, M. C., Borlaug, B. A., Abildstrøm, S. Z., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Verma, S., Einfeldt, M. N., Lindegaard, M. L., Rasmussen, S., Abhayaratna, W., Ahmed, F. Z., Ben-Gal, T., Chopra, V., Ezekowitz, J. A., Fu, M., . . . Kosiborod, M. N. (2024). Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. The Lancet. https://doi.org/10.1016/s0140-6736(24)00469-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.